Boston Immune Technologies & Therapeutics
No bio yet
This person is not in any teams
This person is not in any offices
Boston Immune Technologies & Therapeutics
BITT has developed a platform for targeting the tumor necrosis factor receptor 2 (TNFR2) oncogene and the potent population of TNFR2 Tregs in the tumor microenvironment.